ROSE trial

Study / Research

A phase 2 study that showed Obicetrapib achieved 45-50% LDL lowering as monotherapy and higher in combination with ezetimibe.

Mentioned in 1 video

Videos Mentioning ROSE trial

407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more

407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more

Peter Attia MD

A phase 2 study that showed Obicetrapib achieved 45-50% LDL lowering as monotherapy and higher in combination with ezetimibe.